Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

Inclusion Criteria: * Diagnosed with open angle glaucoma and/or ocular hypertension and not sufficiently responsive to monotherapy. * Meet qualifying IOP criteria in at least 1 eye, including 21-35 mmHg at the Eligibility visit. * Willing to sign an Informed Consent form. * Contact lens wearer who is willing to remove lenses before instillation of study medication and wait a minimum of 15 minutes following drug instillation before re-inserting the lenses. * Able to discontinue use of current IOP-lowering medications per the minimum washout period. * Other protocol-specific inclusion criteria may apply. Exclusion Criteria: * Women of childbearing potential if pregnant, test positive for pregnancy at Screening/Enrollment visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study. * Diagnosed with any form of glaucoma other than open-angle glaucoma and/or ocular hypertension. * Diagnosed with severe central visual field loss in either eye. * History of chronic, recurrent, or severe ocular infection, inflammatory eye disease in either eye. * History of ocular trauma within the past 6 months in either eye. * Current ocular infection or ocular inflammation within the past 3 months in either eye. * Ocular laser surgery within the past 3 months. * Intraocular surgery within the past 3 months. * Best-corrected visual acuity score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen, 0.60 logMAR or 0.25 decimal). * History of, or current clinically relevant or progressive retinal disease in either eye. * History of, or current other severe ocular pathology (including severe dry eye) in either eye, that would preclude the administration of a topical carbonic anhydrase inhibitor (CAI) or beta-blocker. * Any abnormality preventing reliable applanation tonometry. * History of, or current condition or disease that would preclude the safe administration of a topical beta blocker or topical beta-adrenergic blocking agent. * History of spontaneous or current hypoglycemia or uncontrolled diabetes. * History of severe or serious hypersensitivity to CAIs, beta-blockers, or to any components of the study medication. * Less than 30 days stable dosing regimen before the Screening Visit of any medications or substances administered by any route and used on a chronic basis that may have affected IOP. * Recent use of high-dose salicylate therapy. * Anticipated use of any additional topical or systemic ocular hypotensive medication during the study. * Not safely able to discontinue all glucocorticoid medications administered by any route. * Currently on therapy or have been on therapy with another investigational agent within 30 days prior to the Screening Visit. * History of, or current evidence of severe illness or any other conditions which would, in the opinion of the Investigator, make the subject unsuitable for the study. * Other protocol-specific exclusion criteria may apply.